CAR-NK在肿瘤免疫治疗方面的研究进展
|
摘要
自然杀伤细胞(Nature killer cell,NK细胞)是淋巴细胞的一个亚群,不受主要组织相容性复合体(major histocompatibility complex,MHC)分子的限制,无需抗原预先致敏便可杀伤肿瘤靶细胞,在天然免疫中发挥着重要的抗肿瘤作用。嵌合抗原受体(Chimeric antigen receptor,CAR)介导T细胞为主的免疫治疗的迅速发展,具有肿瘤杀伤性的NK细胞在CAR中的应用也受到广泛关注。目前,CAR-NK在各种靶向血液肿瘤、实体瘤的体外实验和动物模型中都取得了明显效果。
Natural killer cells(NK cells) are a subset of lymphocytes that are not restricted by MHC molecules. They can kill tumor target cells without antigen pre-sensitization and play an important anti-tumor role in innate immunity.Chimeric antigen receptor(CAR) mediates the rapid development of T cell-based immunotherapy, and the application of NK cells with tumor-killing activity in CAR has also attracted wide attention. At present, CAR-NK has achieved remarkable results in various in vitro experiments and animal models targeting hematological tumors and solid tumors,and it is hoped that new progress will be made in the future research of tumor immunotherapy.
Natural killer cells(NK cells) are a subset of lymphocytes that are not restricted by MHC molecules. They can kill tumor target cells without antigen pre-sensitization and play an important anti-tumor role in innate immunity.Chimeric antigen receptor(CAR) mediates the rapid development of T cell-based immunotherapy, and the application of NK cells with tumor-killing activity in CAR has also attracted wide attention. At present, CAR-NK has achieved remarkable results in various in vitro experiments and animal models targeting hematological tumors and solid tumors,and it is hoped that new progress will be made in the future research of tumor immunotherapy.
引文
[1]Sahm C,Sch?nfeld K,Wels WS.Expression of IL-15 in NK Cells Results in Rapid Enrichment and Selective Cytotoxicity of GeneModified Effectors that Carry a Tumor-Specific Antigen Receptor[J].Cancer Immunol Immunother,2012,61(9):1451-1461.
[2]Hu Y,Tian ZG,Zhang C.Chimeric Antigen Receptor(CAR)-transduced Natural Killer Cells in Tumor Immunotherapy[J].Acta Pharmacol Sin,2018,39(2):167-176.
[3]Shimasaki N,Fujisaki H,Cho D,et al.A Clinically Adaptable Method to Enhance the Cytotoxicity of Natural Killer Cells against B-cell Malignancies[J].Cytotherapy,2012,14(7):830-840.
[4]Chu Y,Hochberg J,Yahr A,et al.Targeting CD20+Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells in Vitro and in NSG mice[J].Cancer Immunol Res,2015,3(4):333-344.
[5]Sch?nfeld K,Sahm C,Zhang C,et al.Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor[J].MolTher,2015,23(2):330-338.
[6]Liu H,Yang B,Sun T,Lin L,et al.Specific Growth Inhibition of ErbB2Expressing Human Breast Cancer Cells by Genetically Modified NK92Cells[J].Oncol Rep,2015,33(1):95-102.
[7]Li Y,Hermanson DL,Moriarity BS,et al.Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity[J].Cell Stem Cell,2018,23:181-192.
[2]Hu Y,Tian ZG,Zhang C.Chimeric Antigen Receptor(CAR)-transduced Natural Killer Cells in Tumor Immunotherapy[J].Acta Pharmacol Sin,2018,39(2):167-176.
[3]Shimasaki N,Fujisaki H,Cho D,et al.A Clinically Adaptable Method to Enhance the Cytotoxicity of Natural Killer Cells against B-cell Malignancies[J].Cytotherapy,2012,14(7):830-840.
[4]Chu Y,Hochberg J,Yahr A,et al.Targeting CD20+Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells in Vitro and in NSG mice[J].Cancer Immunol Res,2015,3(4):333-344.
[5]Sch?nfeld K,Sahm C,Zhang C,et al.Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor[J].MolTher,2015,23(2):330-338.
[6]Liu H,Yang B,Sun T,Lin L,et al.Specific Growth Inhibition of ErbB2Expressing Human Breast Cancer Cells by Genetically Modified NK92Cells[J].Oncol Rep,2015,33(1):95-102.
[7]Li Y,Hermanson DL,Moriarity BS,et al.Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity[J].Cell Stem Cell,2018,23:181-192.